NEI

Auction Company CEO and Antique Advertising Expert Rich Penn Joins Morphy Auctions In Newly-Created Role of Market Development Officer

Retrieved on: 
Thursday, May 2, 2024
Marketing, Collection, National Auctioneers Association, NEI, Rich, Advertising, Knowledge, Auction

DENVER, Pa., May 2, 2024 /PRNewswire/ -- Dan Morphy, founder and president of Morphy Auctions, has announced that renowned Iowa auction company CEO and antique advertising specialist Rich Penn has joined Morphy's in the newly-created role of Market Development Officer. From his base in Waterloo, Iowa, Penn will be working in tandem with Morphy's marketing team to advise on the latest technological innovations benefiting the auction process. Additionally, he will liaise personally with consignors of antique advertising, toys, country store antiques, classic cars, petroliana, sports memorabilia, and other popular collectibles.

Key Points: 
  • Morphy's to launch series of auctions featuring Rich and Sharon Penn's stellar personal collection of antique advertising and country store antiques, Dec. 6-8, 2024 in Las Vegas
    DENVER, Pa., May 2, 2024 /PRNewswire/ -- Dan Morphy, founder and president of Morphy Auctions, has announced that renowned Iowa auction company CEO and antique advertising specialist Rich Penn has joined Morphy's in the newly-created role of Market Development Officer.
  • Additionally, he will liaise personally with consignors of antique advertising, toys, country store antiques, classic cars, petroliana, sports memorabilia, and other popular collectibles.
  • His sales and ours cover a lot of the same ground and our business principles are very similar," Rich Penn said.
  • As part of the newly-forged agreement, Rich Penn Auctions will continue to conduct online-only timed auctions, but not traditional cataloged auctions.

Northeast Indiana Greenlights Childcare Assistance for Working Families

Retrieved on: 
Wednesday, May 1, 2024
Investment, Education, Health, Committee, General assembly, NEI, Family, Economic development, Training and development, Multimedia, Student, Assembly, Life insurance

FORT WAYNE, Ind., May 1, 2024 /PRNewswire/ -- On Friday, April 26, the Northeast Indiana Strategic Development (NEI SDC) approved investments in two projects to assist working families and accelerate economic development in the region.

Key Points: 
  • Strategic Development Commission Approves $5 Million in Early Childhood Aide, over $100,000 in Forgivable Loans
    FORT WAYNE, Ind., May 1, 2024 /PRNewswire/ -- On Friday, April 26, the Northeast Indiana Strategic Development (NEI SDC) approved investments in two projects to assist working families and accelerate economic development in the region.
  • Northeast Indiana Early Childhood Coalition was approved for an investment of $4,999,669 to support the creation of the "Tri-Share Plus" model to address affordability and accessibility through increased financial aid for working families, while supporting the health of childcare organizations by creating a shared service model for back-office functions.
  • The Tri-Share Plus model splits childcare costs between the state, employer, and family, with each paying one third of the amount.
  • "The Northeast Indiana Strategic Development Commission is thrilled to advance these exciting initiatives with the potential to yield generational returns for our region," said Mayor Strick.

ASP Isotopes Issues Letter to Stockholders

Retrieved on: 
Thursday, April 11, 2024
Consensus, FDA, Nuclear energy, Uranium, Memorandum, Void coefficient, SMR, Intelligence, Prostate cancer, Isotope, ASP, Silicon, Annual report, Yoy, PET, Semiconductor, Private, DOE, Acceleration, Safety, GE HealthCare, Small modular reactor, Artificial intelligence, Coal, Nuclear Energy Institute, Exercise, Isotopes of ytterbium, NEI, Cyclotron, Laser, Radiopharmaceutical, Government, FDG, Silane, Sale, Lithium, Lutetium (177Lu) vipivotide tetraxetan, LEU, Lutetium, Radionuclide, Electronics, ASPI, Letter, Growth, Rare-earth element

WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.

Key Points: 
  • WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.
  • The contract required RC14 to provide an irrevocable standby letter of credit in lieu of a deposit, which was received.
  • Our proprietary technology has proven capabilities to enrich a wide range of isotopes, including light isotopes and lighter molecules, such as silane (SiH4).
  • ASP Isotopes’ goal is to become the lowest cost and most reliable supplier of stable isotopes globally.

Sidus Space Announces Second Agreement with HEO for Non-Earth Imaging Payload and Data Services Aboard Upcoming Lizzie-Sat Launch

Retrieved on: 
Wednesday, April 10, 2024
Mobile, Wireless, Internet, Hardware, Data Management, Technology, Other Communications, Satellite, Engineering, Communications, Aerospace, Manufacturing, Telecommunications, Entrepreneurship, Space Symposium, HEO, NEI, Partnership, Movement, Orbit, Data collection, Spacecraft

Sidus Space, Inc. (NASDAQ: SIDU) (the “Company” or “Sidus”), a multi-faceted Space and Data-as-a-Service satellite company, announced today at the Space Symposium in Colorado Springs that it has finalized an additional agreement with HEO, a leading provider of non-Earth imaging (“NEI”) and data, for NEI payload and data services.

Key Points: 
  • Sidus Space, Inc. (NASDAQ: SIDU) (the “Company” or “Sidus”), a multi-faceted Space and Data-as-a-Service satellite company, announced today at the Space Symposium in Colorado Springs that it has finalized an additional agreement with HEO, a leading provider of non-Earth imaging (“NEI”) and data, for NEI payload and data services.
  • Under the agreement, Sidus Space will host HEO’s NEI imager, HOLMES-006, onboard LizzieSat-3, as part of the Bandwagon-2 launch scheduled for November 2024, along with a monthly data services contract.
  • This marks the second agreement between HEO and Sidus Space, as Sidus Space’s LizzieSat-2 will be hosting HEO’s HOLMES-004 on the same launch.
  • HEO’s Holmes Imager is a telescopic space camera designed and developed to be hosted as a secondary payload on spacecraft.

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Civil service commission, Research, AATD, Growth, Akari, C5, Patient, Choroidal neovascularization, Sale, B4, PRV, Mortality, Hot game, Clinical trial, Therapy, Priority review, Safety, NEI, European Commission, ADC, Geographic atrophy, Hematopoietic stem cell transplantation, CNV, Pharmaceutical industry

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.

Key Points: 
  • BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
  • The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
  • Akari is continuing to recruit patients into the Part A portion of the Phase 3 clinical trial that has treated 10 patients to date.
  • During 2023, Akari also advanced the long-acting version of nomacopan (PASylated nomacopan) into the final stages of pre-clinical development as a treatment for geographic atrophy (GA).

BALTIMORE BRIDGE COLLAPSE AFFECTING RELOCATION

Retrieved on: 
Wednesday, March 27, 2024
NEI, Multimedia, Interstate Highway System, Port, Delays, Interstate 695, Francis Scott Key Bridge, Cargo

OMAHA, Neb., March 27, 2024 /PRNewswire/ -- Early on Tuesday morning, tragedy struck as the Francis Scott Key Bridge in Baltimore, Maryland succumbed to collapse following a collision by the 10,000 container-capacity vessel "Dali" which had lost power while enroute from the U.S. to Colombo, Sri Lanka.

Key Points: 
  • OMAHA, Neb., March 27, 2024 /PRNewswire/ -- Early on Tuesday morning, tragedy struck as the Francis Scott Key Bridge in Baltimore, Maryland succumbed to collapse following a collision by the 10,000 container-capacity vessel "Dali" which had lost power while enroute from the U.S. to Colombo, Sri Lanka.
  • Cargo that was intended for Baltimore will likely be discharged at nearby ports and reach their final destination by landside transportation.
  • The bridge (a part of Interstate 695) offered a key transport link between Washington, Baltimore, Philadelphia, and New York.
  • Delays should be expected on any household goods shipments to/from the Port of Baltimore as well as at nearby ports.

NEI Global Relocation Launches NEI All-Access: A Digital Hub for Global Mobility Leaders

Retrieved on: 
Tuesday, March 26, 2024
NEI, HR, Executive, Policy

OMAHA, Neb., March 26, 2024 /PRNewswire/ -- NEI Global Relocation, a leader in global mobility and relocation services, is proud to announce the launch of NEI All-Access , an exclusive online platform designed for Executives, HR Leaders, and Global Mobility Managers and Specialists.

Key Points: 
  • OMAHA, Neb., March 26, 2024 /PRNewswire/ -- NEI Global Relocation, a leader in global mobility and relocation services, is proud to announce the launch of NEI All-Access , an exclusive online platform designed for Executives, HR Leaders, and Global Mobility Managers and Specialists.
  • NEI All-Access stands out as a critical resource for professionals navigating the complexities of global mobility, offering insights into:
    Strategic Insights and Planning: Discover resources that align global mobility strategies with business objectives, ensuring a cohesive approach to talent management across borders.
  • Professional Empowerment: Engage with materials that foster professional growth and development, enhancing the capabilities of HR and global mobility teams.
  • Trend Spotting and Analysis: Stay ahead of the curve with in-depth analysis on the latest global mobility trends, technologies, and policy changes.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Tuesday, March 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Tuesday, March 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

Retrieved on: 
Thursday, February 22, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Acquisition, PANSS, Blood pressure, KRTX, NEI, FDA, Food, Schizophrenia, PDUFA, Psychiatry, Bristol Myers Squibb, Safety, Psychosis, Therapy, Patient, Congress, Positive, NDA, Pharmaceutical industry

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
  • Results from the EMERGENT-2 trial published in The Lancet in December 2023.
  • Announced positive results from the Phase 1b Ambulatory Blood Pressure Monitoring trial in schizophrenia in the fourth quarter of 2023.
  • Presented additional data from the EMERGENT program at the 2023 Neuroscience Education Institute (NEI) Congress and the CNS Summit in the fourth quarter of 2023.